ArticlePloS one2017
First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 7 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Non-coding RNAs as diagnostic biomarkers for preeclampsia: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2025Pooled it
- Pooled it
- Changes in microRNA expression associated with preeclampsia: a systematic review.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Pooled it
- Circulating miRNAs in the first trimester and pregnancy complications: a systematic review.Epigenetics · 2023Pooled it
- The Value of Circulating microRNAs for Diagnosis and Prediction of Preeclampsia: a Meta-analysis and Systematic Review.Reproductive sciences (Thousand Oaks, Calif.) · 2022Pooled it
- Circulating noncoding RNAs as early predictive biomarkers in preeclampsia: a diagnostic meta-analysis.Reproductive biology and endocrinology : RB&E · 2021Pooled it
- Circulating Nucleic Acids in Maternal Plasma and Serum in Pregnancy Complications: Are They Really Useful in Clinical Practice? A Systematic Review.Molecular diagnosis & therapy · 2020Pooled it
- Pregnancy-related disorders: molecular mechanisms and management.Molecular biomedicine · 2026Review
- Extracellular Vesicle-Associated Non-Coding RNAs in Preeclampsia: Mechanistic Insights, Biomarker Discovery, and Emerging Nanomedicine Concepts.International journal of nanomedicine · 2026Review
- Cell-free RNAs in maternal peripheral blood as potential biomarkers of preeclampsia: a review.Reproductive biology and endocrinology : RB&E · 2025Review
- The Role of Angiogenetic Factors in Preeclampsia.International journal of molecular sciences · 2025Review
- First trimester maternal serum MicroRNA expression and pre-eclampsia: a retrospective nested case-control study.BMC pregnancy and childbirth · 2025Article
- Review
- Molecular Biomarkers for Timely and Personalized Prediction of Maternal-Fetal Health Risk.Biomolecules · 2025Review
- Differential Expression of Maternal Plasma microRNAs and Their Respective Gene Targets Can Predict Early Fetal Growth Restriction.Life (Basel, Switzerland) · 2025Review
- Maternal Diet Quality in Pregnancy and Human Milk Extracellular Vesicle and Particle microRNA.Epigenetics reports · 2025Article
- First Trimester Placental Biomarkers for Pregnancy Outcomes.International journal of molecular sciences · 2024Review
- Article
- Hemostasis in Pre-Eclamptic Women and Their Offspring: Current Knowledge and Hemostasis Assessment with Viscoelastic Tests.Diagnostics (Basel, Switzerland) · 2024Review
- Circulating miRNAs and Preeclampsia: From Implantation to Epigenetics.International journal of molecular sciences · 2024Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesA nested case control study of a longitudinal cohort comparing pregnant women enrolled at 10 to 13 gestational weeks was carried out to evaluate risk assessment for preeclampsia and IUGR based on circulating placental specific C19MC microRNAs in early pregnancy.
methodsThe expression of placental specific C19MC microRNAs (miR-516b-5p, miR-517-5p, miR-518b, miR-520a-5p, miR-520h, and miR-525-5p) was determined in plasma samples from pregnancies that subsequently developed preeclampsia (n = 21), IUGR (n = 18), and 58 normal pregnancies using real-time PCR and comparative Ct method relative to synthetic Caenorhabditis elegans microRNA (cel-miR-39).
resultsCirculating C19MC microRNAs were up-regulated (miR-517-5p, p = 0.005; miR-518b, p = 0.013; miR-520h, p = 0.021) or showed a trend toward up-regulation in patients destined to develop preeclampsia (miR-520a-5p, p = 0.067; miR-525-5p, p = 0.073). MiR-517-5p had the best predictive performance for preeclampsia with a sensitivity of 42.9%, a specificity of 86.2%, a PPV of 52.9% and a NPV of 80.6%. The combination of all examined circulating C19MC microRNAs had no advantage over using only the miR-517-5p biomarker to predict the occurrence of preeclampsia (a sensitivity of 20.6%, a specificity of 90.8%, a PPV of 44.8%, and a NPV of 76.0%).
conclusionsUp-regulation of miR-517-5p, miR-518b and miR-520h was associated with a risk of later development of preeclampsia. First trimester screening of extracellular miR-517-5p identified a proportion of women with subsequent preeclampsia. No circulating C19MC microRNA biomarkers were identified that could predict later occurrence of IUGR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.